Drug Profile
Research programme: chimeric antigen receptor T cell therapeutics - BioInvent/Unknown
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator BioInvent International; Unknown
- Developer BioInvent International
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
- 17 Jun 2015 Early research in Cancer in Sweden (unspecified route)